Home › Kidney Cancer (Renal Cell Carcinoma) › Michigan
Kidney Cancer (Renal Cell Carcinoma) clinical trials in Michigan
29 studies for Kidney Cancer (Renal Cell Carcinoma) are looking for participants at sites in Michigan.
Cities in Michigan
- Ann Arbor12 studies
- Detroit10 studies
- Grand Rapids10 studies
- Canton5 studies
- Livonia5 studies
- Lansing4 studies
- Dearborn4 studies
- Flint3 studies
- Warren3 studies
- Waterford3 studies
- Farmington Hills3 studies
- Troy3 studies
- Kalamazoo3 studies
- Wyoming3 studies
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Research Site, Detroit
- Research Site, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05536141Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
- NEO-811 Grand Rapids Site, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07300241A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- and 68 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #65, Detroit
- Exelixis Clinical Site #13, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- and 32 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
- Local Institution - 0176, Big Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07293351Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- START Midwest, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05267626Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALA
- Henry Ford Health, Detroit
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 18, 2026 · NCT07828704Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- University of Michigan Rogel Cancer Center, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- and 12 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05327686A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- University of Michigan, Ann Arbor
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07195916ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cancer & Hematology Centers of Western Michigan, Grand Rapids
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- Bronson Battle Creek, Battle Creek
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- and 17 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06661720A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07115043Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
- University of Michigan, Ann Arbor
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06966024A Study of MGC026 in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06242470Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
- University of Michigan Comprehensive Cancer Center, Ann Arbor
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT06866262Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Henry Ford Cancer Institute, Detroit
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 29, 2026 · NCT04198766A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- Henry Ford Health, Detroit
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT03972657Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT07383441KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Henry Ford Health System, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 8, 2026 · NCT06026410Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 252010, Ann Arbor
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT04777994Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
- University of Michigan, Ann Arbor
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT06053658A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
- Start Midwest Cancer Research, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 28, 2026 · NCT06413680Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- Henry Ford Cancer Institute, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 17, 2025 · NCT05856981A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- University of Michigan Hospitals, Ann Arbor
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2025 · NCT06805825Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- University of Michigan Comprehensive Cancer Center, Ann Arbor
- Bronson Battle Creek, Battle Creek
- University of Michigan - Brighton Center for Specialty Care, Brighton
- and 15 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT04510597A Beta-only IL-2 ImmunoTherapY Study
- Karmanos Cancer Institute, Detroit
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 9, 2025 · NCT05086692A Study of IBI363 in Subjects with Advanced Solid Malignancies
- Michigan Hematology & Oncology Consultants - MedOnc Dearborn, Dearborn
- Michigan Hematology & Oncology Consultants - MedOnc Troy, Troy
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 19, 2024 · NCT06281678From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.